Clonality assurance and the rise of therapeutic monoclonal antibody development

Monoclonal antibodies – a recent history Over three decades ago, in 1986, the first monoclonal antibody (mAb) treatment was approved by the United States Food and Drug Administration (US FDA)[1]. Since then, techniques and technologies to identify, engineer and harness mAbs have advanced and therapeutic antibodies have become the primary focus for many drug developers. …

Read more Clonality assurance and the rise of therapeutic monoclonal antibody development

Solentim to launch the ICON™ in 2021

Solentim is happy to announce that its new Cell Line Development platform, the ICON, will launch early 2021. For over a decade, Solentim has provided leading solutions to create, isolate and characterize the highest value cells, accelerating the development of new biological medicines and therapies around the world, in cell line development, vaccine research, stem …

Read more Solentim to launch the ICON™ in 2021

Is it time for a new standard for the culture of iPSCs?

For those delivering advanced therapy medicinal products, the question of assessing and managing cell population heterogeneity presents an ongoing challenge. Solentim and EverCell Bio addressed this topic at a recent webinar during which they discussed the use of induced pluripotent stem cells (iPSCs) and sharing data from EverCell Bio’s iPSC lines when moving into the clinic. …

Read more Is it time for a new standard for the culture of iPSCs?

Solentim to supply cell line development solutions for Samsung Biologics’ new R&D center in San Francisco

Bournemouth, UK, 7th October 2020 / Solentim is pleased to announce the adoption of its VIPS™ single cell seeding platform and Cell Metric® CLD into Samsung Biologics’ new research and development facility in San Francisco, CA. These instruments are designed for single cell cloning and assurance of monoclonality to increase the speed and efficiency of Master Cell Bank development. Samsung’s new R&D …

Read more Solentim to supply cell line development solutions for Samsung Biologics’ new R&D center in San Francisco

Solentim launches new workflow for single cell cloning of stem cells

VIPS™ + MatriClone™ combination ensures high efficiency seeding of hiPSCs with high viability Solentim, the global leader for solutions to create, isolate and characterize the highest value cells for the development of new biological medicines, yesterday launched a dedicated new workflow for single cell cloning of human induced pluripotent stem cells (hiPSCs). A combination of Solentim’s VIPS™ (verified in-situ plate seeding) instrument …

Read more Solentim launches new workflow for single cell cloning of stem cells

Service and support: Service Status Certification for laboratory accreditation

The quality of a cell line development (CLD) process is dependent on the optimization of many discrete, measurable stages. When considering the optimization of instruments used in CLD workflows, using technology that is fit for purpose, installed, maintained, operated and functioning correctly, and used by staff who are trained correctly, all contribute to a quality …

Read more Service and support: Service Status Certification for laboratory accreditation